0112 GMT - IHH Healthcare's earnings outlook may remain attractive amid rising demand and revenue intensity, particularly in the Indian and Malaysian markets, as key growth drivers, Maybank IB analysts Yin Shao Yang and Nur Natasha Ariza say in a note. Despite the stock's over 20% year-to-date share price gains, valuations indicate potential for a re-rating as IHH pursues both organic and strategic inorganic expansion, they add. The analysts project a 13% compound annual growth rate in three-year forward revenue and Ebitda for IHH. Maybank resumes coverage on IHH with a buy rating and raises its target price to MYR7.97 from MYR7.13. Shares are unchanged at MYR7.23. (yingxian.wong@wsj.com)
(END) Dow Jones Newswires
December 29, 2024 20:12 ET (01:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.